Drug biomarker resources for precise translational research

用于精准转化研究的药物生物标志物资源

• 批准号: 10056488
• 负责人: Bin Chen
• 金额: $ 5.82万
• 依托单位: MICHIGAN STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-01-24 至 2020-04-07
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10056488
• 关键词: Adopted; BRAF gene; Biological Markers; Biology; Cancer Patient; Cell Line; Clinic; Clinical Trials; Computer software; Data; Disease; Ensure; Epidermal Growth Factor Receptor; Funding; Gefitinib; Genes; Goals; Health system; Informatics; Investigation; Investigational Drugs; Knowledge; Label; Lead; Link; Machine Learning; Malignant neoplasm of lung; Manuals; Medical Students; Mining; Modeling; Modernization; Molecular Profiling; Mutate; Mutation; Ontology; Patient Recruitments; Patients; Pharmaceutical Preparations; Pharmacogenomics; Positioning Attribute; Publications; Research; Resources; Sampling; Scientist; Signs and Symptoms; Source; Supervision; Text; Training; Translational Research; United States National Institutes of Health; Work; base; biomarker discovery; crowdsourcing; data resource; deep learning; improved; in silico; individual patient; knowledge graph; learning strategy; melanoma; molecular scale; mouse model; mutant; new therapeutic target; novel; novel marker; ontology development; optimal treatments; patient population; pre-clinical; precision medicine; preclinical study; recruit; specific biomarkers; tool

One goal of precision medicine is to select optimal therapies for individual patients based on drug biomarkers as well as disease symptoms/signs 1–3. The clinic has started to treat patients based on biomarkers. Examples include Gefitinib used to treat lung cancer patients with mutant EGFR and Vemurafenib used to treat melanoma patients with the BRAF V600E mutation. Clinical trials have also been tailored to recruit patients with the presence of specific biomarkers. A variety of preclinical studies have been conducted to discover biomarkers of investigational drugs. Recent large-scale molecular profiling of cell lines and pharmacogenomics even enables the prediction of biomarkers in silico. All these confirmed or investigational biomarkers (in silico, preclinical, in clinic) have emerged as critical components in modern translational research. However, our current knowledge about biomarkers is scattered and locked away in different places, including FDA labels, clinical trial descriptions, or publications, presenting a significant barrier to integrating them into knowledge graphs to augment reasoning. Therefore, we propose to create a novel composite knowledge source for biomarker discovery. This new source will improve the quality and quantity of connections between drug-biomarker-disease-patient and synthesize new knowledge for precision medicine research. To comply with established standards and aid the implementation of data/software standards for Translator, we will first develop an ontology to define biomarkers and their relationships with other biomedical entities. Next, we will leverage state of the art deep learning methods to extract biomarkers from publications and clinical trials. We will further adopt a crowd-sourcing approach using a large pool of medical students to manually inspect and curate biomarkers prioritized by our machine learning models. The machine learning models will be iteratively improved through a semi-supervised approach. To ensure high quality of provided knowledge, multiple lines (in silico, preclinical, in clinic) of evidence along with confidence scores will be associated with each biomarker. Through collaborating with NCATS staff, we will link biomarkers to other available resources to augment reasoning. We expect that the resource will be a critical component of a knowledge graph, enabling the query of novel questions related to precision medicine and the building of AI models. For example, can drug x work in a mouse model y where gene z is mutated? In what patient population may drug x be effective? Can drug x be repurposed to treat condition m where the biomarker of drug x is presented? Can we find new drugs/targets for those patients with the absence of the biomarker for the approved drug? Moreover, the labeled and well-curated data along with molecular profiles provide AI-ready resources for novel biomarker discovery that could be further validated by bench scientists. To achieve the goal, we have assembled an outstanding team comprising experts in biology, informatics, machine learning, ontology, and knowledge graph. Through two NIH-funded biomarker discovery projects, PI Dr. Chen has gained extensive knowledge in biomarker discovery, collected compelling use cases with bench collaborators, and built a tool for precision medicine. Co-I Dr. Duesbery, a biologist by training and Director of Research at Spectrum Health System, will lead the inspection of biomarkers using real-world data. By combining expertise of Dr. Krishnan who has built deep-learning methods to annotate disease samples from free-text, and Dr. Ding who specializes in ontology development and knowledge graph construction and mining, the team is well-positioned to accomplish the goals of this project. Potential challenges include the recruitment of domain experts to validate biomarkers for a wide range of diseases, the integration with the data provided in other projects, and the limited data resources to cover all diseases. The exploratory study in the first two segments will enable a better estimation of these challenges.

精准医疗的目标之一是根据药物为个体患者选择最佳治疗方法